Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.88 | 8.84 | 9.69 | 13.43 |
| FCF Yield | -3.51% | 0.81% | 2.81% | 2.54% |
| EV / EBITDA | 17.65 | 15.47 | 14.55 | 20.21 |
| Quality | ||||
| ROIC | 8.21% | 8.99% | 9.35% | 9.20% |
| Gross Margin | 52.90% | 55.56% | 55.53% | 57.18% |
| Cash Conversion Ratio | 0.81 | 0.67 | 1.14 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.13% | 3.76% | 3.37% | -2.61% |
| Free Cash Flow Growth | -421.08% | -69.45% | -13.98% | -8.08% |
| Safety | ||||
| Net Debt / EBITDA | -2.28 | -2.10 | -3.00 | -3.07 |
| Interest Coverage | 887.86 | 888.97 | 1,481.61 | 1,448.06 |
| Efficiency | ||||
| Inventory Turnover | 3.23 | 3.49 | 4.18 | 4.40 |
| Cash Conversion Cycle | 183.38 | 134.11 | 103.19 | 116.82 |